Guangzhou Kingmed Diagnostics Group Co., Ltd.
SSE:603882.SS
28.52 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 7,189.545 | 8,539.628 | 15,476.075 | 11,943.224 | 8,243.764 | 5,269.266 | 4,525.253 | 3,791.718 | 3,221.58 | 2,389.392 | 1,837.858 | 1,356.071 | 977.202 |
| Cost of Revenue
| 4,806.526 | 5,424.536 | 8,801.575 | 6,295.018 | 4,395.136 | 3,189.147 | 2,767.98 | 2,238.786 | 1,857.304 | 1,292.068 | 1,002.916 | 758.749 | 591.86 |
| Gross Profit
| 2,383.019 | 3,115.092 | 6,674.499 | 5,648.206 | 3,848.627 | 2,080.12 | 1,757.273 | 1,552.932 | 1,364.276 | 1,097.324 | 834.941 | 597.321 | 385.342 |
| Gross Profit Ratio
| 0.331 | 0.365 | 0.431 | 0.473 | 0.467 | 0.395 | 0.388 | 0.41 | 0.423 | 0.459 | 0.454 | 0.44 | 0.394 |
| Reseach & Development Expenses
| 400.469 | 467.139 | 632.618 | 517.928 | 397.17 | 324.023 | 290.847 | 255.984 | 238.211 | 221.022 | 161.131 | 115.75 | 42.609 |
| General & Administrative Expenses
| 159.65 | 240.377 | 388.766 | 364.042 | 244.389 | 185.413 | 170.678 | 167.765 | 114.844 | 94.592 | 173.36 | 235.418 | 130.425 |
| Selling & Marketing Expenses
| 429.095 | 541.942 | 1,513.646 | 1,438.576 | 992.631 | 806.4 | 703.682 | 638.228 | 591.603 | 456.522 | 345.253 | 271.901 | 185.116 |
| SG&A
| 588.745 | 2,089.975 | 1,902.412 | 1,802.618 | 1,237.02 | 991.813 | 874.36 | 805.993 | 706.447 | 551.114 | 518.613 | 507.319 | 315.54 |
| Other Expenses
| 1,667.049 | 0 | 542.096 | 452.75 | 316.356 | 266.9 | 8.817 | 9.277 | 42.125 | 26.868 | 12.386 | 12.448 | 10.484 |
| Operating Expenses
| 2,656.263 | 2,355.33 | 3,077.127 | 2,773.296 | 1,950.546 | 1,582.735 | 1,397.481 | 1,248.226 | 1,136.913 | 901.362 | 771.533 | 508.269 | 316.606 |
| Operating Income
| -273.244 | 759.762 | 3,347.234 | 2,776.768 | 1,816.865 | 484.035 | 311.959 | 262.545 | 188.976 | 162.775 | 40.266 | 72.063 | 56.967 |
| Operating Income Ratio
| -0.038 | 0.089 | 0.216 | 0.232 | 0.22 | 0.092 | 0.069 | 0.069 | 0.059 | 0.068 | 0.022 | 0.053 | 0.058 |
| Total Other Income Expenses Net
| -165.403 | -19.474 | -26.505 | -29.21 | -6.391 | 15.137 | 8.817 | 9.277 | 12.752 | 27.19 | -50.705 | -5.033 | -1.439 |
| Income Before Tax
| -438.647 | 740.289 | 3,320.73 | 2,747.557 | 1,810.474 | 495.724 | 320.776 | 271.823 | 230.828 | 189.146 | 52.255 | 84.019 | 67.297 |
| Income Before Tax Ratio
| -0.061 | 0.087 | 0.215 | 0.23 | 0.22 | 0.094 | 0.071 | 0.072 | 0.072 | 0.079 | 0.028 | 0.062 | 0.069 |
| Income Tax Expense
| -23.943 | 103.38 | 477.746 | 384.046 | 237.041 | 80.459 | 65.382 | 63.721 | 44.505 | 45.452 | 12.166 | 24.077 | 16.037 |
| Net Income
| -381.241 | 643.382 | 2,754.787 | 2,219.64 | 1,509.702 | 402.331 | 233.321 | 188.505 | 170.035 | 131.431 | 31.256 | 52.447 | 44.085 |
| Net Income Ratio
| -0.053 | 0.075 | 0.178 | 0.186 | 0.183 | 0.076 | 0.052 | 0.05 | 0.053 | 0.055 | 0.017 | 0.039 | 0.045 |
| EPS
| -0.82 | 1.38 | 5.9 | 4.8 | 3.29 | 0.88 | 0.51 | 0.46 | 0.44 | 0.38 | 1.58 | 0.15 | 0.13 |
| EPS Diluted
| -0.82 | 1.38 | 5.89 | 4.76 | 3.27 | 0.88 | 0.51 | 0.46 | 0.44 | 0.38 | 1.58 | 0.15 | 0.13 |
| EBITDA
| 133.812 | 1,452.404 | 3,979.773 | 3,201.084 | 2,120.584 | 789.908 | 623.055 | 481.551 | 409.577 | 300.378 | 118.992 | 125.538 | 96.9 |
| EBITDA Ratio
| 0.019 | 0.17 | 0.257 | 0.268 | 0.257 | 0.15 | 0.138 | 0.127 | 0.127 | 0.126 | 0.065 | 0.093 | 0.099 |